First, we demonstrated the effect of FGL1 suppression on sorafenib resistance using high FGL1-expressing HCC cell lines, but did not overexpress FGL1 in low FGL1-expressing cells. This evidence concerns the gene FGL1 and hepatocellular carcinoma.